William Blair Weighs in on Charles River Laboratories Intl. Inc’s Q1 2018 Earnings (CRL)

Charles River Laboratories Intl. Inc (NYSE:CRL) – William Blair dropped their Q1 2018 earnings estimates for Charles River Laboratories Intl. in a report released on Tuesday. William Blair analyst J. Kreger now anticipates that the medical research company will post earnings per share of $1.24 for the quarter, down from their prior estimate of $1.32. William Blair also issued estimates for Charles River Laboratories Intl.’s Q2 2019 earnings at $1.67 EPS, Q3 2019 earnings at $1.62 EPS, Q4 2019 earnings at $1.68 EPS and FY2019 earnings at $6.53 EPS.

Charles River Laboratories Intl. (NYSE:CRL) last announced its earnings results on Tuesday, February 13th. The medical research company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.26 by $0.14. The company had revenue of $478.50 million for the quarter, compared to analysts’ expectations of $475.02 million. Charles River Laboratories Intl. had a return on equity of 26.14% and a net margin of 6.64%. The business’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.21 earnings per share.

Several other analysts have also recently commented on CRL. Zacks Investment Research upgraded Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 target price on the stock in a report on Tuesday, October 24th. Bank of America cut their price target on Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, November 10th. ValuEngine lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Robert W. Baird set a $117.00 price target on Charles River Laboratories Intl. and gave the company a “buy” rating in a research note on Monday, November 13th. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $113.00 price target on shares of Charles River Laboratories Intl. in a research note on Friday, November 17th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $114.85.

Shares of Charles River Laboratories Intl. (CRL) opened at $110.31 on Thursday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.62 and a current ratio of 1.78. The company has a market capitalization of $5,106.20, a price-to-earnings ratio of 43.43, a PEG ratio of 1.60 and a beta of 0.74. Charles River Laboratories Intl. has a 1-year low of $86.25 and a 1-year high of $119.05.

Large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its stake in Charles River Laboratories Intl. by 1,071.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,054 shares of the medical research company’s stock valued at $115,000 after buying an additional 964 shares during the period. YorkBridge Wealth Partners LLC lifted its stake in Charles River Laboratories Intl. by 445.5% in the third quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock valued at $118,000 after buying an additional 891 shares during the period. Ladenburg Thalmann Financial Services Inc. lifted its stake in Charles River Laboratories Intl. by 69.0% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock valued at $145,000 after buying an additional 548 shares during the period. Advisor Group Inc. lifted its stake in Charles River Laboratories Intl. by 159.4% in the third quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock valued at $165,000 after buying an additional 945 shares during the period. Finally, Zions Bancorporation acquired a new position in Charles River Laboratories Intl. in the third quarter valued at about $212,000. 97.13% of the stock is currently owned by hedge funds and other institutional investors.

In other Charles River Laboratories Intl. news, insider David Ross Smith sold 5,486 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $109.53, for a total value of $600,881.58. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director C Richard Reese sold 10,227 shares of the stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $102.40, for a total value of $1,047,244.80. Following the completion of the transaction, the director now directly owns 51,444 shares in the company, valued at approximately $5,267,865.60. The disclosure for this sale can be found here. Insiders have sold 195,673 shares of company stock worth $2,644,046 in the last ninety days. 2.20% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/02/15/william-blair-weighs-in-on-charles-river-laboratories-intl-incs-q1-2018-earnings-crl.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply